Edition:
United States

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

140.05USD
24 Mar 2017
Change (% chg)

$0.92 (+0.66%)
Prev Close
$139.13
Open
$139.83
Day's High
$141.41
Day's Low
$139.04
Volume
122,882
Avg. Vol
250,556
52-wk High
$169.58
52-wk Low
$97.70

Latest Key Developments (Source: Significant Developments)

United Therapeutics, Northwell Health's Feinstein Institute announce partnership
Thursday, 9 Mar 2017 06:00am EST 

United Therapeutics Corp : United Therapeutics - co, Northwell Health's Feinstein Institute for Medical Research announced strategic partnership . United Therapeutics Corp - under partnership, united therapeutics will fund Northwell's efforts in four research and development tracks .United Therapeutics -partnership for application of bioelectronic medicine, cell therapy to cardiology, hypertension, post-transplant tolerance induction.  Full Article

United Therapeutics reports Q4 non-GAAP eps of $4.12
Wednesday, 22 Feb 2017 06:00am EST 

United Therapeutics Corp : United Therapeutics Corporation reports 2016 fourth quarter and annual financial results . Q4 revenue $409 million . Q4 revenue view $415.5 million -- Thomson Reuters I/B/E/S . Qtrly earnings per share $2.43 . Qtrly non-GAAP earnings per share $4.12 .Q4 earnings per share view $3.61 -- Thomson Reuters I/B/E/S.  Full Article

United Therapeutics reports Q3 EPS $3.50
Thursday, 27 Oct 2016 06:00am EDT 

United Therapeutics Corp : United therapeutics corporation reports third quarter 2016 financial results . United therapeutics corp - qtrly earnings per share $ 3.50 . United therapeutics corp - qtrly adjusted earnings per share $ 4.36 . Qtrly non-gaap earnings, per diluted share $ 4.36 . United therapeutics corp - qtrly revenues $ 408.2 million versus. $ 386.2 million .Q3 earnings per share view $3.34, revenue view $402.4 million -- Thomson Reuters I/B/E/S.  Full Article

United Therapeutics Corp Q2 income per diluted share $4.39
Thursday, 28 Jul 2016 06:00am EDT 

United Therapeutics Corp Qtrly Non : United Therapeutics Corp qtrly net income, per diluted share $4.39 . Q2 earnings per share view $3.22, revenue view $395.0 million -- Thomson Reuters I/B/E/S . United Therapeutics Corporation reports second quarter 2016 financial results . Q2 revenue $400 million versus I/B/E/S view $395 million .Gaap earnings, per diluted share $4.55.  Full Article

United Therapeutics Corp says Roger Jeffs steps down as president and co-CEO
Thursday, 28 Apr 2016 06:31am EDT 

United Therapeutics Corp:Says Roger Jeffs steps down as president and co-chief executive officer.Says David Zaccardelli steps down as executive vice president and chief operating officer.United Therapeutics Corp says David Zaccardelli, steps down as executive vice president and chief operating officer.United Therapeutics Corp says Michael Benkowitz promoted to president and chief operating officer.United Therapeutics Corp says Martine Rothblatt, remains chairman of board and becomes sole chief executive officer.Says Michael Benkowitz promoted to president and chief operating officer.United therapeutics corp says Jeffs will become a senior advisor to company.  Full Article

United Therapeutics Corp announces additional $500 million share repurchase program
Thursday, 15 Oct 2015 06:00am EDT 

United Therapeutics Corp:Says authorized the repurchase of up to an additional $500 million of the company's common stock.Says program will become effective on January 1, 2016, and will remain open for up to one year.  Full Article

United Therapeutics Corp announces settlement of patent litigation with Sandoz Inc.
Wednesday, 30 Sep 2015 06:00am EDT 

United Therapeutics Corp:Says it has entered into a settlement agreement with Sandoz Inc relating to ongoing litigation concerning certain patents.Says under the settlement Agreement, United Therapeutics granted to Sandoz a non-exclusive license to manufacture and commercialize the generic version of Remodulin, although Sandoz may be permitted to enter the market earlier under certain circumstances.Says the settlement agreement does not grant Sandoz any rights other than those required to launch Sandoz's generic version of Remodulin.  Full Article

United Therapeutics Corporation agrees to sell priority review voucher to AbbVie
Wednesday, 19 Aug 2015 06:00am EDT 

United Therapeutics Corporation:Announces that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PPRV) to a subsidiary of AbbVie Inc.Says upon closing of the transaction, United Therapeutics will receive $350 million in cash in exchange for the PPRV.  Full Article

More From Around the Web

BRIEF-United Therapeutics, Northwell Health's Feinstein Institute announce partnership

* United Therapeutics - co, Northwell Health's Feinstein Institute for Medical Research announced strategic partnership